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Abstract
Background: The current fourth paper on the International College of Neuropsychopharmacology guidelines for the treatment 
of bipolar disorder reports on the unmet needs that became apparent after an extensive review of the literature and also 
serves as a conclusion to the project of the International College of Neuropsychopharmacology workgroup.
Materials and Methods: The systematic review of the literature that was performed to develop the International College of 
Neuropsychopharmacology guidelines for bipolar disorder identified and classified a number of potential shortcomings.
Results: Problems identified concerned the reliability and validity of the diagnosis of bipolar disorder and especially of bipolar 
depression. This, in turn, has profound consequences for early detection and correct treatment of the disorder. Another 
area that needs improvement is the unsatisfactory efficacy and effectiveness of therapeutic options, especially in special 
populations such as those with mixed features and rapid cycling course. Gender issues and adherence problems constitute 
an additional challenge. The literature suggests that while treatment providers are concerned more with treatment-related 
issues, patients and their caregivers worry more about issues pertaining to the availability of services and care, quality of life, 
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and various types of burden. The workgroup identified additional unmet needs related to the current standard of research in 
bipolar disorder. These include the fragmentation of bipolar disorder into phases that are handled as being almost absolutely 
independent from each other, and thus the development of an overall therapeutic strategy on the basis of the existing 
evidence is very difficult. Trials are not always designed in a way that outcomes cover the most important aspects of bipolar 
disorder, and often the reporting of the results is biased and unsatisfactory. The data on combination treatments and high 
dosages are sparse, whereas they are common in real world practice.
Conclusions: The workgroup endorses the full release of raw study data to the scientific community, and the development of 
uniform clinical trial standards (also including more realistic outcomes) and the reporting of results. The 2 large appendices 
summarize the results of this systematic review with regard to the areas of lack of knowledge where further focused research 
is necessary.
Keywords: BD, anticonvulsants, antidepressants, antipsychotics, evidence-based guidelines, lithium, mania, bipolar 
depression, mood stabilizers, treatment
Background
The first 3 papers of the International College of 
Neuropsychopharmacology (CINP) guidelines for the treatment 
of bipolar disorder (BD) consisted of a systematic and exhaust-
ing review of the literature concerning the available hard data on 
treatment options and a description of the major clinical chal-
lenges the therapist faces together with the patient and his/her 
family.
The workgroup developed a precise experimental algorithm 
and a clinical guideline for the treatment of BD, but it is obvi-
ous that these products are far from perfect. In fact there are a 
significant number of issues and needs that were not addressed 
due to a lack of evidence-based data. Suboptimal treatment and 
management, however, puts the patients at a higher risk for 
an adverse outcome with more residual symptoms and higher 
disability.
This is of utmost importance, since BD is a rather common and 
complex mental disorder accompanied by significant morbidity 
and mortality, including a high rate of suicide, while it is obvious 
that the treatment needs are not fully met by currently available 
pharmacotherapies and psychosocial interventions of any kind. 
The problem is further complicated by the poor adherence to 
treatment that many patients show and the somatic comorbidi-
ties that in some cases are adverse effects of medication.
The current paper is the fourth and last of the initiative to 
develop CINP guidelines for the treatment of BD and summa-
rizes the experience gained from the whole project. It identifies 
the unmet needs and makes suggestions for future research and 
the way of dealing with specific issues in BD.
1. Unmet Needs Identified in the Literature 
(Summarized in Tables 1 and 2)
Diagnosis
The first and maybe biggest problem in the management of BD is 
the difficulty in making early correct diagnosis (Lish et al., 1994; 
Lewis, 2000; Hirschfeld et al., 2003; Morselli et al., 2003). In a major-
ity of patients the first episode is depressive, and thus they receive 
the diagnosis of unipolar depression and they are mistreated with 
antidepressant monotherapy (Vieta, 2014). It has been reported 
that as many as 70% of BD patients failed to receive a correct 
diagnosis in the 1-year period following the initial episode, and in 
approximately 35% of them the correct diagnosis has been made 
only after 10 years had passed (Lish et al., 1994) Additionally, up to 
70% of BD patients but especially bipolar spectrum patients often 
go unrecognized and undiagnosed, and thus remain untreated or 
inappropriately treated (Hirschfeld et  al., 2003; Frye et  al., 2004; 
Ketter, 2010). Since BD patients are most often misdiagnosed as 
suffering from unipolar depression or some type of personality 
disorder, they are frequently treated with antidepressants only 
or an inappropriate type of psychotherapy for prolonged periods 
of time.
This problem may persist until the day psychiatric diagno-
sis is not exclusively based on clinical phenotypes but on reli-
able and valid biological markers that can be utilized for precise 
diagnostic differentiation and treatment planning. Of all mental 
disorders, BD is the one that will probably benefit the most from 
the introduction of reliable and valid biological markers to our 
diagnostic armamentarium.
Additionally, physical health problems, especially in bipo-
lar spectrum patients, are underrecognized and undertreated 
(Merikangas et  al., 2011). This is probably a consequence of 
stigma but also of an unhealthy lifestyle, poor treatment adher-
ence, and only irregular contacts with health care services.
Efficacy and Effectiveness of Therapeutic Options
All authors agree that only 2 to 3 agents have some efficacy 
across all phases, and no single pharmacotherapy is currently 
achieving remission in a satisfactory proportion of BD patients 
both across all phases and in the long term. Acute episodes 
comprise a relatively small time share of the overall illness, but 
subthreshold or subclinical symptoms dominate the clinical 
picture for most of the duration of the lives of patients, causing 
significant impairment, disability, and burden (Judd et al., 2002, 
2003; Morgan et al., 2005). Since no single pharmacologic treat-
ment is likely to achieve all therapeutic objectives, combining 
treatments is usually necessary to achieve an acceptable quality 
of life (Grande et al., 2016).
The very concept of what constitutes a “mood stabilizer” is 
under dispute, since there is no agent that is efficacious against 
all phases and all major clinical features of BD (manic, mixed, 
and depressive episodes, rapid cycling). Historically, lithium, 
valproate, and carbamazepine have all been considered to act as 
mood stabilizers, but today we have to acknowledge that some 
atypical antipsychotics, namely quetiapine and olanzapine, do 
also fulfil many criteria of a mood stabilizer. When it comes to 
clinical usefulness, while antipsychotics may act faster in acute 
mania and are also definitely efficacious against psychotic fea-
tures, there are concerns with the safety profile of all agents 
useful in the treatment of BD, such as metabolic syndrome with 
antipsychotics, kidney and thyroid issues with lithium.
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Almost all the literature concerning the treatment of all 
phases of BD focuses on reporting changes from baseline in a 
symptom rating scale and neglects other important aspects, 
including disability, quality of life, burden, and economic issues. 
Most researchers agree that currently available treatments are 
more efficacious in the reduction of symptoms than in the 
improvement of disability and the overall outcome (Bauer et al., 
2001a; Calabrese et al., 2014; Frye et al., 2014; McElroy, 2014). This 
is especially true concerning bipolar depression, which is a rather 
refractory mental state with high risk for suicide (Akiskal et al., 
1983; Weissman et al., 1984; Frye et al., 2004, 2014) and profound 
and lasting functional impairment (Bonnin et al., 2015). Residual 
symptoms may interfere with the ability of the patients to access 
and benefit from health care but also from the general state wel-
fare (Gerson and Rose, 2012). Particularly in those patients with 
more severe disability, functional decline, and poor quality of life, 
the overall burden is further increased by a higher mortality from 
comorbid medical conditions (McIntyre et al., 2007) and suicide 
(Morgan et al., 2005). In these cases, the burden is also higher for 
caregivers, and the increased service utilization leads to a higher 
overall cost. This is made even worse when discriminatory cover-
age and reimbursement policies for mental health care are in 
place as they are in many countries around the world (Charney 
et al., 2003; Morgan et al., 2005).
It is unfortunate (although the reasons are apparent) that, 
by far, fewer randomized controlled trials (RCTs) have been 
conducted on the treatment of acute bipolar depression than 
for acute mania (Han et al., 2013). The changing composition of 
the study samples is a developing problem for all RCTs in men-
tal disorders, and it seems that nowadays larger numbers of 
patients are required to demonstrate a significant effect com-
pared with earlier studies, although the reasons for this are not 
entirely understood (Sachs, 2003).
Comprehensive managed care comprising of intensive fol-
low-up, psychosocial and psychological treatment, and func-
tional rehabilitation is not easily accessible to patients, even in 
developed countries. Lack of access to such services probably 
adversely influences the overall long-term outcome (Morgan 
et al., 2005; Goossens et al., 2007).
Gender
While it is known that there are gender-specific factors that can 
influence the treatment and overall management of patients 
with BD (Leibenluft, 1996; Hendrick et al., 2000; Leibenluft, 2000; 
Curtis, 2005), little research has been conducted in this area. 
This is important since unmet needs could differ between males 
and females (Curtis, 2005; Morgan et al., 2005).
Although the prevalence of BD-I is similar between genders 
(Morgan et al., 2005), more females suffer from BD-II (Leibenluft, 
1996) and depressive predominant polarity (Nivoli et al., 2011). 
In addition, rapid cycling, mixed episodes, and dysphoric mania 
but also hypothyroidism and personality disorders might be 
more prevalent in females (McElroy et  al., 1992; Arnold et  al., 
2000; Judd et  al., 2002; Post et  al., 2003; Morgan et  al., 2005), 
while suicidality, psychotic features, and hospitalizations are 
more frequently seen in males (Morgan et al., 2005). There is a 
greater incidence of a childhood history of sexual abuse among 
female patients (Hyun et al., 2000), and this is probably true also 
for adulthood (Coverdale and Turbott, 2000). A history of sexual 
abuse or the high risk to become a victim might justify nursing 
the patient in a single-sex environment, although such environ-
ments are vanishing. There are some data suggesting a differ-
ent risk depending on gender comorbid alcohol and substance 
abuse (Hendrick et al., 2000; Frye et al., 2003). As protective fac-
tors, female patients with BD less often stay single or are without 
children and less frequently live alone. They seem to maintain 
better global functioning compared with male patients with BD 
(Morgan et al., 2005).
The most prominent issues with female BD patients are 
around the reproductive cycle and related physiology. While the 
influence of the menstrual cycle and menopause on the course 
of BD is still unclear, there are some research data on the effects 
of motherhood. It is simply reasonable that in the case of a preg-
nant patient, multidisciplinary care together with the obstetri-
cian and midwife is mandatory.
The most commonly emerging issues concern unwanted 
pregnancy (Coverdale et  al., 1997). Therefore, bipolar women 
of childbearing age should receive intense counseling regard-
ing effective contraceptive practice, issues pertaining to inter-
action of contraceptive pills with medication for BD, and the 
possible effects of pregnancy and delivery on the course of 
bipolar illness. Also the treatment options during pregnancy 
and breast feeding should be discussed along with the psy-
chological and somatic stress of pregnancy and child-rearing, 
and the effects treatment might have on the fetus depending 
on the trimester of gestation. Finally, counselling about the 
genetic risk of BD should be offered also to siblings to enable 
informed decisions for future pregnancies (Packer, 1992; Cohen 
et  al., 1994). In everyday practice, few patients consider the 
risks related to pregnancy unacceptable, and these should be 
guided to use effective contraception, which should be consid-
ered together with the medication the patient receives to treat 
BD. Several drugs, for example carbamazepine, oxcarbazepine, 
lamotrigine, and topiramate, all increase the clearance rate 
of oral contraceptives, and thus the doses of oral contracep-
tive for patients taking these medications need to be adjusted 
and/or other protective strategies need to be implemented as 
a standard of care.
According to some studies, pregnancy is associated with a 
reduced overall risk for psychiatric admission (Kendell et  al., 
1987) and a lower risk for suicide (Appleby, 1991; Marzuk et al., 
1997) and may improve the clinical course of BD (Sharma and 
Persad, 1995; Grof et al., 2000), but there are also reports of the 
opposite (Blehar et al., 1998; Freeman et al., 2002). On the other 
hand, there is a broad consensus that the postpartum period 
confers the greatest risk for exacerbation of BD (usually within 
90 days) (Dunner et al., 1979; Brockington et al., 1981; Davidson 
and Robertson, 1985; Kendell et al., 1987; Schopf and Rust, 1994; 
Leibenluft, 1996; Blehar et al., 1998; Freeman et al., 2002).
Besides the issues concerning the reproductive cycle, female 
patients appear to be at greater risk for a number of medica-
tion adverse effects, including weight gain (Fakhoury et al., 2001; 
Russell and Mackell, 2001) and extreme obesity (McElroy et al., 
2002) and decrease in bone mineral density as a result of pro-
longed hyperprolactinemia (Wieck and Haddad, 2003), which 
could also cause a hypogonadal state (Smith et al., 2002).
The Therapists’ Point of View
There is not much data concerning the point of view of psy-
chiatrists and of therapists in general on the unmet needs in the 
treatment of BD patients.
One study reported that psychiatrists in the UK and US con-
sider education and support for patients and families as well 
as earlier referral to specialist care as the highest ranked needs 
at entry into care. On the other hand, they thought that dur-
ing treatment of acute episodes and also during the long-term 
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management, the most important needs were improved effec-
tiveness of treatments and patient adherence in addition to 
improved long-term safety in the maintenance phase. These 
mental health professionals ranked patients with comorbid 
alcohol and/or substance use disorders as having the high-
est level of unmet need, followed by rapid-cycling patients 
(Chengappa and Williams, 2005).
A second study reported that clinicians were not adherent 
to evidence-based practice and that their clinical practice was 
not consistent with the results of clinical trial data or current 
guideline recommendations. Additionally, there seems to be an 
unmet need for education to enable psychiatrists to differenti-
ate between unipolar and bipolar depression, to identify the risk 
of treatment-emergent mood disorders with the use of antide-
pressants, and to effectively manage patients at risk for BD-I. 
It is surprising that only one-half of the respondents thought 
that treatment guidelines should be important in their everyday 
clinical practice, and additionally they also reported that clinical 
trial results were the least influential. Furthermore, only one-
third of the respondents were familiar with large practical clini-
cal trials and scientific associations, organizations, and other 
bodies relating to BD (Glauser et al., 2013). Overall, the findings 
clearly indicate that many clinicians are not well informed about 
the evidence base of their treatment choices for BD patients, 
especially for depressive symptoms, and they are also not well 
trained concerning the clinical assessment and management of 
BD (Han et al., 2013). Guidelines to provide comprehensive intro-
ductory information, suggestions, and resources for caregivers 
have been developed to assist them to formulate treatment 
strategies ranging from a stepped-care approach to supporting 
caregivers, ranging from basic information and pamphlets to 
brief training courses and specialized family or caregiver inter-
ventions based on need and accessibility (Berk et al., 2011).
The Patients’ and Caregivers’ Point of View
It is well known that different “stakeholders” emphasize differ-
ent unmet needs, and therefore the point of view of patients 
and caregivers might vary considerably from the point of view 
Table 1. Unmet Needs in the Treatment of BD Patients Identified in 
the Literature
Diagnosis char="12"
• Early correct diagnosis
• Recognition and treatment of somatic health problems
Efficacy and effectiveness of therapeutic options
• Only 2–3 agents are efficacious across all phases
• The definition of ‘mood stabilizer’ is problematic
• Combining treatments is usually necessary to achieve an 
acceptable level of efficacy
• Research so far neglects outcomes like disability, quality of life, 
burden, and economic issues
• Limited data on treatments for acute bipolar depression
• Lack of access to specialized care services
Gender
• Little research on gender issues
• There are some data suggesting that gender is related to different 
clinical pictures, adverse events profile and to different outcomes
• Issues related to female physiology and reproduction, especially 
pregnancy and breast feeding
Unmet needs: the therapists’ point of view
• Education and support for patients and families
• Earlier referral to specialist care
• Improved effectiveness and patient adherence
• A minority of therapists adheres to evidence-based standards
• There is an unmet need for the continuous education of 
professionals
Unmet needs: the patients’ and caregivers’ point of view
• Clinical research never focuses on the unmet needs as the 
patients conceive them
• The generalizability of research data to the real-world patient is 
unknown
• Burden of caregivers of patients
Adherence to treatment
• Psychoeducation is not routinely applied at the earlier stages
• Empowerment of service users is not the standard
Table 2. Unmet Needs in the Treatment of BD Patients As Identified 
During the Process of Guideline Development
Fragmentation of BD as a disorder char="12"
• Research does not consider BD as a single disorder but as a 
sequence of largely independent phases
• Almost impossible to reliably transform the available data into a 
longitudinal treatment strategy
Unsatisfactory design of RCTs
• Scales do not cover the full symptomatology of BD
• Recognition and reporting of diagnostic criteria and specifiers is 
problematic
• Duration too short for acute mania and acute bipolar depression 
studies
• Duration of the continuation phase too short before entering the 
maintenance phase
• Use of enriched samples almost in all maintenance studies
• Research on substance and alcohol abuse and medical 
comorbidities is insufficient
Focus on more realistic outcomes
• General impairment and disability
• Neurocognitive function
• Social and occupational functioning
• Quality of life
Limited data concerning combination treatment and high dosages
Incomplete results reporting
• Core symptoms of mania or depression
• Mixed features




• Incomplete descriptive statistics
Reporting of the results
• Inconsistent way of reporting
• Often different study samples sizes are reported in different 
documents concerning the same study
• Last Observation Carried Forward vs Mixed-Effect Model Repeated 
Measure
Table 3. Recommendations of the Workgroup for Further Research
Availability of the raw data char="12"
Study design
• Study any acute mood episode with the same broad protocol
• Anxiety and psychotic symptoms should also be assessed
• Assessment of neurocognitive function in long-term studies
• Assessment of disability and social and occupational functioning 
and quality of life
• Adequate duration of studies
• Separate studies of both enriched and nonenriched samples in 
maintenance studies
• Studies focusing on mixed depression
Proposed template for a standardized reporting of the results (see 
appendix)
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of mental health professionals (Chengappa and Goodwin, 2005). 
What may contribute to poor adherence is the fact that clin-
ical research hardly focuses on the unmet needs as the patients 
perceive them and therefore, at least to some extent, real world 
needs are not addressed (Bauer, 2002). Even more, it is not 
known to what extend clinical trials data apply to those patients 
who are not eligible to be included in standardized controlled 
research, because they suffer from multiple comorbidities or 
have shown refractoriness to treatment in the past (Wells, 1999; 
Bauer et al., 2001b; Simon et al., 2002; Wells et al., 2002; Sachs 
et al., 2003; Bauer and Mitchner, 2004). There is also profound 
discrepancy between the interpretation by mental health pro-
fessionals of the evidence base for treatments in BD and patient 
perception of the relative effectiveness of different treatment 
options (Masand and Tracy, 2014).
If the real outcome of mental disease is what patients report 
concerning their quality of life, research gives a grim picture 
with patients with severe mental illness reporting dissatisfac-
tion with their social functioning and general health and unmet 
needs concerning case management services, social and rec-
reational activities, and vocational rehabilitation (Badger et al., 
2003).
Caregivers of patients with BD may experience a different 
quality of burden than is seen with other illnesses, and it is 
definitely more severe compared with the burden of caregiv-
ers of patients with unipolar depression. However, there is not 
enough research data on this issue, which is largely neglected 
(Reinares et al., 2006). Conceptualizing the burden of a bipolar 
caregiver in a conventional medical framework may not focus 
enough on important issues or on cultural and social issues as 
well as on the objective and subjective aspects of burden. An 
important fact is that burden to caregivers is associated with 
caregiver depression, which conversely affects patient recovery 
by adding stress to the home environment. It is also associated 
with high levels of expressed emotion, including critical, hos-
tile, or over-involved attitudes. It is reasonable to assume that it 
is not possible to ameliorate service provision without a better 
understanding of caregiver burden and the means to measure 
and target it (Ogilvie et al., 2005).
Adherence to Treatment
Poor treatment adherence is a major problem in mental health 
care, and especially in BD it is associated with poor outcome 
(Keck et al., 1996; Bauer et al., 2001a). Depending on definition 
and setting, it has been reported that between one- and two-
thirds of BD patients are noncompliant with treatment (Johnson 
and McFarland, 1996; Keck et  al., 1996; Murru et  al., 2013). 
Adverse events are one of the reasons patients are often unwill-
ing to continue medication treatment for prolonged periods 
of time. Some might also wish to continue to have the expe-
rience of manic or especially of hypomanic episodes, which 
are particularly pleasant. Psychoeducation and collaborating 
with patients and caregivers enables patients to be active par-
ticipants in the management process, and this is believed to 
improve treatment adherence (Sachs, 2013). It is interesting to 
note that both patients and their families often seemed to lack a 
thorough understanding of disease management goals and the 
need for follow-up care (Lish et al., 1994).
Therefore, there seems to be a clear need for more empower-
ment of patients and their caregivers. Currently they appear less 
than optimally informed concerning the need and benefits of 
continuation treatment and care, with the result of high rates of 
poor treatment adherence.
2. Unmet Needs Identified by the CINP 
Guidelines Project
As described and reported in the previous papers of the CINP 
guidelines, the workgroup synthesized and analyzed the acces-
sible data on the efficacy of existing treatment options for BD. 
The essential result was a large table of efficacy data for each 
treatment option across different phases of the illness and con-
sidering specific clinical features. The analysis, classification, 
and tabulation of the results revealed a number of important 
problems and unmet needs as well as areas that should be the 
focus of research in the future.
Fragmentation of BD As a Disorder
A major problem of the literature is that it is almost impossible 
to reliably assemble the available data in a longitudinal treat-
ment strategy that would take into consideration the present 
phase but also the psychiatric history and possible future devel-
opment. That is, the data do not consider BD as a single dis-
order but as separate and literally independent phases. At the 
guidelines but also the clinical level, it creates a very important 
dilemma. What should the decision for the maintenance treat-
ment be in case the patient was treated (and responded to) with 
a treatment with no data concerning the long-term prophylac-
tic treatment, or even worse with negative data concerning the 
assumed possible future of his or her mental health? For exam-
ple, a patient has responded favorably to haloperidol during an 
acute manic episode, but since the patient’s history indicates 
that the overwhelming majority of the mood episodes were 
depressive episodes (depressive predominant polarity), it is fair 
to assume that these episodes will continue to be frequent. In 
such a case, the therapist is left with a dilemma: should he or 
she add an agent with proven preventive efficacy against depres-
sive episodes, for example quetiapine, and apply combination 
treatment, or should he or she change to monotherapy with an 
agent with proven prophylactic efficacy against both poles? The 
answer is not apparent and different opinions do exist, espe-
cially since almost all maintenance studies include enriched 
samples, that is samples of patients who responded during the 
acute phase specifically to the agent under research. Especially 
in cases of partial or poor response to first line treatment, it 
is unknown which would be the best next option. Switching 
might prolong suffering while adjunctive treatment will result 
in polypharmacy.
Future research should focus on these problems and provide 
specific answers. Ideally, all treatment options should be tested 
against all phases and clinical features of BD, and those with 
broader efficacy should receive priority in the use. Of course safety 
and tolerability issues might additionally perplex the problem.
Unsatisfactory Design of RCTs
The inclusion of too many scales probably creates severe prob-
lems with the completion of RCTs; however, the trials should 
include those scales that have been proven to be of high impor-
tance for everyday clinical practice. In addition, reporting should 
not only include global measures but inform professionals 
more specifically which diagnostic features and specifiers of BD 
responded to a given treatment. However, the total costs of a 
trial and the feasibility need to be balanced against the research 
benefits.
In this framework, the design of future clinical trials should 
take into consideration that outcomes should address issues 
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like mixed features, anxiety, psychotic symptoms, neurocog-
nitive disorder, and disability. Currently there are few data on 
mixed features in acute bipolar depression, and almost all data 
on mixed episodes come from acute mania trials. At the same 
time, the overall design should keep the effort for the patients 
and the researchers at a minimum by avoiding unnecessary rat-
ings and making RCTs feasible.
An important concern to mention is the duration of the con-
tinuation phase before entering the maintenance phase, which 
is often unacceptably short. This is sometimes the case for acute 
phase studies and especially for bipolar depression. Since the 
aripiprazole studies had positive results at week 6 but negative 
at endpoint, which was week 8 (Thase et al., 2008), it is reason-
able to suggest that the minimum duration for acute bipolar 
depression studies should be 8 weeks to capture true and lasting 
improvement. However, this is not always the case, and at least 
one agent gained approval with a positive study of only 6 weeks 
duration (Loebel et al., 2014).
While the enriched designs inform about the longer term effi-
cacy of an agent if it was effective for an acute phase, they do not 
provide information about whether or not they have broader spec-
trum of prophylactic efficacy (i.e., prophylactic efficacy in patients 
who responded to other agents during acute phase). While many 
agents that are effective in acute phase appear to provide benefit 
during the maintenance phase, it is unknown whether this can 
be generalized to all agents for the maintenance period.
In acute mania, a study duration of 3 weeks appears not 
adequate; however, most studies utilized this short duration. 
Probably the best solution would be to utilize a 12-week design 
both in acute mania and depression RCTs that may allow for 
assessing both manic and depressive symptoms that often 
coexist. The use of placebo is acceptable, but ideally a third arm 
with a comparator would be more informative for assay sensi-
tivity (Vieta and Cruz, 2012).
Research on substance and alcohol abuse and medical 
comorbidities should be a specific target of research and prob-
ably cannot be incorporated in the frame of the standard RCTs. 
Large observational studies may be needed to supplement con-
trolled trials.
Focus on More Realistic Outcomes
Almost all the RCTs are industry sponsored, and therefore their 
primary aim is to obtain labelling for the product. Thus, the pri-
mary outcome is always the change in the total score of a scale 
that measures the symptoms of the acute phase (YMRS, MRS, 
MADRS, or the HAM-D), while the CGI or the PANSS are included as 
secondary outcomes. Rates of response and remission are almost 
always included as secondary outcomes. Relapse into a mood epi-
sode is the most usual primary outcome for maintenance studies.
It is very rare that measurements of general impairment, 
neurocognitive function, social and occupational quality of life, 
etc. are utilized. Although the currently used outcomes serve 
the purpose to test whether the agent under consideration is 
efficacious or not, they fail to capture aspects of treatment that 
are equally clinically relevant and of high importance for the 
everyday clinical practice.
Limited Data Concerning Combination Treatment 
and High Dosages
While in everyday clinical practice polypharmacy is the rule 
rather than the exception, the research data in support of most 
combination options are weak or absent. This is also the case with 
the use of high dosages, which is often everyday clinical practice.
Incomplete Results Reporting
Although the data are often available, the authors and the 
manufacturers decide not to report them. Examples include the 
effect of treatment options on the core symptoms of mania or 
depression and on mixed features, psychotic symptoms, rapid 
cycling, etc. Often only P values are reported without means 
and SDs and at other times the opposite happens, thus adding 
confusion. In many instances, total scale scores with problem-
atic interpretation (e.g., total PANSS score) are reported with-
out a more detailed subanalysis. Sometimes the data are not 
available for the entire study sample and thus different sample 
sizes apply for each outcome; however, this is not always made 
transparent. It is unacceptable that usually in mixed episodes 
only the effect of the treatment modality on the manic compo-
nent is reported but the effect on the depressive component is 
missing.
It is desirable for the raw data to be released and accessible 
for the scientific community. Much advancement in our know-
ledge and ability to treat BD patients better may arise not from 
new and expensive research but from simply exhaustively ana-
lyzing existing data. The release of the raw data will also remove 
publication bias and improve the reliability of conclusions.
Reporting of the Results
The overall impression from the review of the literature is 
that the results are reported in a nonhomogenous way and 
although some kind of a template exists, it is not always pos-
sible to detect and extract all details. This is a particular prob-
lem when extracting data to perform meta-analysis. Important 
details are often missing, for example, the score on the posi-
tive subscale of the PANSS, while others that are less important 
exist, for example, the PANSS total score. In most instances, a 
Last Observation Carried Forward approach is utilized while in 
a minority the Mixed-Effect Model Repeated Measure is used. 
In some cases the results are reported selectively from either 
model. Each model/approach has its advantages and disadvan-
tages (Siddiqui et al., 2009). It is also dubious that often different 
numbers for study samples are found in different publications 
of the same original study. It is also important that reports fulfil 
the CONSORT requirements.
3. Recommendations for Future Research 
Policies (Summarized in Table 3)
Availability of the Raw Data
The wealth of data that has been accumulated but not exhaus-
tively analyzed is huge. The full release of these data will not 
only provide us with answers to a number of questions but it 
will also eliminate much of the publication bias that makes con-
clusions difficult. One of the most important questions that, if 
not answered, then at least could lead to a much better under-
standing is which (if any) baseline clinical characteristics pre-
dict response to specific treatments.
Since for the vast majority of treatment options the patents 
have expired, there is no practical reason for the industry to jus-
tify the withholding of the data except of a possible loss of face 
if a previously biased reporting becomes apparent. However, 
even in the case of those agents still under patent, the benefit 
for the public health should be considered as more important 
than any supposed commercial interest. In any case, this should 
be considered to be a matter of transparency.
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Study Design
Future RCTs conducted for licensing purposes will probably 
need to consider any acute mood episode in a similar way. 
Since pure episodes of either pole are not the rule but rather the 
exception and with the “mixed features” specifier in place by 
the DSM-5, it is important to assess the presence of depressive 
symptoms in acute mania and manic symptoms in acute bipo-
lar depression. In either case, anxiety and psychotic symptoms 
should also be assessed. This means that in all RCTs, YMRS or 
MRS, MADRS or HAM-D, HAM-A, and PANSS need to be included. 
It is desirable although difficult to include regular assessments 
of neurocognitive function especially in maintenance studies. 
For long-term studies, the assessment of disability and espe-
cially of social and occupational functioning and quality of life 
should be mandatory.
Template for a Standardized Reporting of the Results
As already mentioned, there is a need to standardize the report-
ing of RCT results and make sure that not only all important 
results are released but also in a manner that adds to our 
understanding of the treatment of BD and also makes further 
analysis possible. Such standardization will also increase the 
reliability of the reports and eliminate the reporting of slightly 
different results in different articles concerning the same study. 
A proposed template for the reporting of RCT results is shown 
in the appendix. The template is laid out for 2 arms (agent vs 
placebo), and in cases of different design (no placebo or 3-arm 
design) it should be modified accordingly. It is suggested that 
both the results according to Last Observation Carried Forward 
and Mixed-Effect Model Repeated Measure should be reported. 
Also it seems important to have a standardized list of adverse 
events and procedure how to capture them, so that it will be 
easy to compare across studies. The template presented in 
the appendix is a convenient summary that can be used as a 
guide as to which results could be of importance and should 
be reported.
4. Discussion
It is clear that unmet clinical needs exist for all phases of BD. 
While the review of the literature suggests that early and reli-
able diagnosis as well as gaps in the education of patients and 
their families could constitute the biggest unmet needs in the 
area of BD, the experience from the analysis of the existing evi-
dence identified additional important problems concerning the 
available knowledge and the way research is carried out.
One important conclusion is that the existing data may 
already provide answers to a number of clinical questions, 
including the specific treatment of subgroups of patients. 
However, relevant analyses have not been carried out and 
the raw data are not released. Taking full advantage of the 
data already gathered might have an impact that will have 
a greater impact in the short term than any new research. 
There is a pressing need and it is for the benefit of public 
health that the data should be released and such analyses 
are carried out.
On the other hand, it is also evident that a standardized 
design for future RCTs is desirable that reflects the complex 
clinical picture of BD, with the simultaneous rating of manic, 
depressive, and psychotic symptoms during all phases of the 
disorder. The design should be standardized to avoid biases 
and uncertainties that are frequent because of the current way 
things are carried out.
A standardized way of reporting the results also seems 
necessary, since currently only a small and often patchy part 
of the results is available. It is not unusual that different docu-
ments that all report the results of the same trial include slightly 
different figures. This raises the issue of overall reliability on 
the current mode of scientific reporting. Besides reporting and 
appraising the evidence, guidelines should also be educational 
and promote good practice. The authors hope that the CINP 
guidelines on BD will have a positive impact on the method-
ology of future patient-orientated research.
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